These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 35787918

  • 1. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D.
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [Abstract] [Full Text] [Related]

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 3. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 4. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 5. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.
    Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, Yang Y, Wu S, Yin D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0185422. PubMed ID: 35862963
    [Abstract] [Full Text] [Related]

  • 6. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V, Principe L, Andriani L, Aiezza N, Coppi M, Ricci S, Giani T, Luzzaro F, Rossolini GM.
    Clin Microbiol Infect; 2023 Apr 31; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [Abstract] [Full Text] [Related]

  • 7. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J, Asar L, Klupp EM, Both A, Rothe C, König C, Rohde H, Kluge S, Maurer FP.
    PLoS One; 2018 Apr 31; 13(4):e0195757. PubMed ID: 29649276
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
    Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C, ARTEMIS Study Investigators.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0383623. PubMed ID: 38483164
    [Abstract] [Full Text] [Related]

  • 9. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R, Park TE, Moy S.
    Clin Ther; 2016 Mar 02; 38(3):431-44. PubMed ID: 26948862
    [Abstract] [Full Text] [Related]

  • 10. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L.
    Clin Microbiol Rev; 2020 Dec 16; 34(1):. PubMed ID: 33177185
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.
    Cruz-López F, Martínez-Meléndez A, Morfin-Otero R, Rodriguez-Noriega E, Maldonado-Garza HJ, Garza-González E.
    Front Cell Infect Microbiol; 2022 Dec 16; 12():884365. PubMed ID: 35669117
    [Abstract] [Full Text] [Related]

  • 12. Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
    Zollner-Schwetz I, König E.
    Curr Opin Urol; 2023 May 01; 33(3):173-179. PubMed ID: 36861769
    [Abstract] [Full Text] [Related]

  • 13. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates.
    Shortridge D, Kantro V, Castanheira M.
    Microbiol Spectr; 2023 Feb 14; 11(1):e0450722. PubMed ID: 36622238
    [Abstract] [Full Text] [Related]

  • 14. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS, Loeb M, Leto D, Brooks AA.
    Postgrad Med; 2020 Apr 14; 132(3):234-250. PubMed ID: 31608743
    [Abstract] [Full Text] [Related]

  • 15. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 14; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 16. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS, Loeb M, Brooks AA.
    Postgrad Med; 2017 Mar 14; 129(2):242-258. PubMed ID: 27712137
    [Abstract] [Full Text] [Related]

  • 17. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
    Rando E, Novy E, Sangiorgi F, De Pascale G, Fantoni M, Murri R, Roberts JA, Cotta MO.
    Int J Antimicrob Agents; 2024 Sep 14; 64(3):107266. PubMed ID: 38971203
    [Abstract] [Full Text] [Related]

  • 18. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Jean SS, Liu IM, Hsieh PC, Kuo DH, Liu YL, Hsueh PR.
    Int J Antimicrob Agents; 2023 May 14; 61(5):106763. PubMed ID: 36804370
    [Abstract] [Full Text] [Related]

  • 19. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS, Pogue JM.
    Pharmacotherapy; 2015 Oct 14; 35(10):949-62. PubMed ID: 26497481
    [Abstract] [Full Text] [Related]

  • 20. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H, Ouweini AEL, Chahine EB, Karaoui LR.
    Am J Health Syst Pharm; 2021 Mar 31; 78(8):674-683. PubMed ID: 33580649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.